Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patterns of transmitted HIV drug resistance in Europe vary by risk group

D. Frentz, D. van de Vijver, A. Abecasis, J. Albert, O. Hamouda, L. Jørgensen, C. Kücherer, D. Struck, JC. Schmit, J. Vercauteren, B. Asjö, C. Balotta, C. Bergin, D. Beshkov, R. Camacho, B. Clotet, A. Griskevicius, Z. Grossman, A. Horban, T....

. 2014 ; 9 (4) : e94495.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008107

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). CONCLUSIONS: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.

Centre Hospitalier de Luxembourg Luxembourg

Centro de Malária e outras Doenças Tropicais Instituto de Higiene e Medicina Tropical Universidade Nova de Lisboa Lisboa Portugal

Department of Clinical Microbiology Karolinska University Hospital Stockholm Sweden

Department of GU Medicine and Infectious Diseases St James's Hospital Dublin Ireland

Department of Microbiology Tumor and Cell Biology Karolinska Institutet Stockholm Sweden

Department of virology Erasmus Medical Center Rotterdam the Netherlands

Department of Virology National Center of Infectious and Parasitic Diseases Sofia Bulgaria

Divisions of Infectious Diseases and Clinical Virology Karolinska Institute Stockholm Sweden

Hospital Egas Moniz Centro Hospitalar de Lisboa Ocidental Lisboa Portugal

Infectology Center of Latvia Riga Latvia

irsiCaixa AIDS Research Institute and Lluita contra la SIDA Foundation Hospital Universitari Germans Trias i Pujol Badalona Spain

Laboratory of Retrovirology CRP Santé Luxembourg Luxembourg

Medical School University of Athens Athens Greece

Medical University Vienna Vienna Austria

Molecular Diagnostics Prof Dr Matei Bals Institute for Infectious Diseases Bucharest Romania

National Institute for Health and Welfare Helsinki Finland

National Institute of Public Health Prague Czech Republic

National Public Health Surveillance Laboratory Vilnius Lithuania

Rega Institute Katholieke Universiteit Leuven Leuven Belgium

Robert Koch Institute Berlin Germany

Section for Microbiology and Immunology The Gade Institute University of Bergen Bergen Norway

Sheba Medical Center Tel Hashomer Israel

Slovak Medical University Bratislava Slovakia

Statens Serum Institute Copenhagen Denmark

University of Belgrade School of Medicine Belgrade Serbia

University of Cyprus Nicosia Cyprus

University of Erlangen Nuremberg Erlangen Germany

University of Ljubljana Ljubljana Slovenia

University of Milan Milan Italy

Warsaw Medical University and Hospital of Infectious Diseases Warsaw Poland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008107
003      
CZ-PrNML
005      
20151019155746.0
007      
ta
008      
150306s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0094495 $2 doi
035    __
$a (PubMed)24721998
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Frentz, Dineke $u Department of virology, Erasmus Medical Center, Rotterdam, the Netherlands.
245    10
$a Patterns of transmitted HIV drug resistance in Europe vary by risk group / $c D. Frentz, D. van de Vijver, A. Abecasis, J. Albert, O. Hamouda, L. Jørgensen, C. Kücherer, D. Struck, JC. Schmit, J. Vercauteren, B. Asjö, C. Balotta, C. Bergin, D. Beshkov, R. Camacho, B. Clotet, A. Griskevicius, Z. Grossman, A. Horban, T. Kolupajeva, K. Korn, L. Kostrikis, KL. Linka, C. Nielsen, D. Otelea, D. Paraskevis, R. Paredes, M. Poljak, E. Puchhammer-Stöckl, A. Sönnerborg, D. Stanekova, M. Stanojevic, AM. Vandamme, C. Boucher, A. Wensing, . ,
520    9_
$a BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). CONCLUSIONS: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.
650    _2
$a dospělí $7 D000328
650    _2
$a látky proti HIV $x terapeutické užití $7 D019380
650    12
$a virová léková rezistence $7 D024882
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x farmakoterapie $x epidemiologie $x přenos $x virologie $7 D015658
650    _2
$a HIV-1 $x účinky léků $7 D015497
650    _2
$a heterosexualita $x statistika a číselné údaje $7 D020010
650    _2
$a homosexualita mužská $x statistika a číselné údaje $7 D018451
650    _2
$a lidé $7 D006801
650    _2
$a logistické modely $7 D016015
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a inhibitory proteas $x terapeutické užití $7 D011480
650    _2
$a inhibitory reverzní transkriptasy $x terapeutické užití $7 D018894
650    _2
$a riziko $7 D012306
650    12
$a riskování $7 D012309
650    _2
$a sexuální chování $x statistika a číselné údaje $7 D012725
650    _2
$a intravenózní abúzus drog $x epidemiologie $x virologie $7 D015819
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van de Vijver, David $u Department of virology, Erasmus Medical Center, Rotterdam, the Netherlands.
700    1_
$a Abecasis, Ana $u Centro de Malária e outras Doenças Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal. $7 gn_A_00000505
700    1_
$a Albert, Jan $u Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. $7 gn_A_00003446
700    1_
$a Hamouda, Osamah $u Robert Koch Institute, Berlin, Germany.
700    1_
$a Jørgensen, Louise $u Statens Serum Institute, Copenhagen, Denmark.
700    1_
$a Kücherer, Claudia $u Robert Koch Institute, Berlin, Germany.
700    1_
$a Struck, Daniel $u Laboratory of Retrovirology, CRP-Santé, Luxembourg, Luxembourg.
700    1_
$a Schmit, Jean-Claude $u Laboratory of Retrovirology, CRP-Santé, Luxembourg, Luxembourg; Centre Hospitalier de Luxembourg, Luxembourg.
700    1_
$a Vercauteren, Jurgen $u Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium.
700    1_
$a Asjö, Birgitta $u Section for Microbiology and Immunology, The Gade Institute, University of Bergen, Bergen, Norway. $7 gn_A_00009400
700    1_
$a Balotta, Claudia $u University of Milan, Milan, Italy.
700    1_
$a Bergin, Colm $u Department of GU Medicine & Infectious Diseases, St James's Hospital, Dublin, Ireland.
700    1_
$a Beshkov, Danail $u Department of Virology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
700    1_
$a Camacho, Ricardo $u Centro de Malária e outras Doenças Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal; Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.
700    1_
$a Clotet, Bonaventura $u irsiCaixa AIDS Research Institute & Lluita contra la SIDA Foundation, Hospital Universitari "Germans Trias i Pujol," Badalona, Spain.
700    1_
$a Griskevicius, Algirdas $u National Public Health Surveillance Laboratory, Vilnius, Lithuania.
700    1_
$a Grossman, Zehava $u Sheba Medical Center, Tel Hashomer, Israel.
700    1_
$a Horban, Andrzej $u Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland.
700    1_
$a Kolupajeva, Tatjana $u Infectology Center of Latvia, Riga, Latvia.
700    1_
$a Korn, Klaus $u University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Kostrikis, Leondios $u University of Cyprus, Nicosia, Cyprus.
700    1_
$a Linka, Kirsi Liitsola Marek $u National Institute for Health and Welfare, Helsinki, Finland; National Institute of Public Health, Prague, Czech Republic.
700    1_
$a Nielsen, Claus $u Robert Koch Institute, Berlin, Germany.
700    1_
$a Otelea, Dan $u Molecular Diagnostics, "Prof Dr Matei Bals" Institute for Infectious Diseases, Bucharest, Romania.
700    1_
$a Paraskevis, Dimitrios $u Medical School, University of Athens, Athens, Greece.
700    1_
$a Paredes, Roger $u Department of Virology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
700    1_
$a Poljak, Mario $u University of Ljubljana, Ljubljana, Slovenia.
700    1_
$a Puchhammer-Stöckl, Elisabeth $u Medical University Vienna, Vienna, Austria.
700    1_
$a Sönnerborg, Anders $u Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden; Divisions of Infectious Diseases and Clinical Virology, Karolinska Institute, Stockholm, Sweden.
700    1_
$a Stanekova, Danica $u Slovak Medical University, Bratislava, Slovakia.
700    1_
$a Stanojevic, Maja $u University of Belgrade School of Medicine, Belgrade, Serbia.
700    1_
$a Vandamme, Anne-Mieke $u Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium.
700    1_
$a Boucher, Charles $u Department of virology, Erasmus Medical Center, Rotterdam, the Netherlands.
700    1_
$a Wensing, Annemarie
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 4 (2014), s. e94495
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24721998 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20151019155939 $b ABA008
999    __
$a ok $b bmc $g 1065380 $s 890907
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 4 $d e94495 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Možnosti archivace